Search clinical trials for: FF/GSK573719

Total 146 results

GlaxoSmithKline

Completed

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma (ILA115938)

Asthma

Argentina, Russian Federation, United States, Chile, Thailand
GlaxoSmithKline

Completed

Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study of GSK573719 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Pulmonary Disease, Chronic Obstructive

Czechia, Hungary
GlaxoSmithKline

Completed

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Hungary, Slovakia
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719 in Japanese (AC4115361)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline
Hammersmith Medicines Research

Completed

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
GlaxoSmithKline

Completed

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Germany, Japan, United States
Queen's University
GlaxoSmithKline

Completed

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

COPD

Canada
GlaxoSmithKline

Completed

A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

Pulmonary Disease, Chronic Obstructive

Netherlands
GlaxoSmithKline

Completed

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

Asthma

Netherlands
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United States
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

AML, Adult

United States
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
Guy's and St Thomas' NHS Foundation Trust

Unknown

Fibrillatory Factor in Ventricular Tachycardia

Ventricular Tachycardia

United Kingdom
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

AML | MDS | CMML

United States
GlaxoSmithKline

Withdrawn

Aura Adolescent PK Study GSK2829332

Asthma
Centre Hospitalier William Morey - Chalon sur Saône
Centre Hospitalier Universitaire Dijon

Recruiting

Dynamic Full-Field Optical Coherence Tomography for Structural and Microbiological Characterization of Central Venous Catheter-deposited Biofilm in Critically Ill Patients (OCT-BIO-CVC)

Critically Ill | Central Venous Catheter Associated Bloodstream Infection | Healthcare Associated Infection

France
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Rectal Cancer

United States
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects (DB2113208)

Pulmonary Disease, Chronic Obstructive

Australia
University of Colorado, Denver
National Institute on Aging (NIA)

Active, not recruiting

VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP) (VITAL-NP)

Suspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)

United States
GlaxoSmithKline

Recruiting

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Asthma

United States
GlaxoSmithKline

Recruiting

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Asthma

China
GlaxoSmithKline

Completed

A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine

Rhinitis, Allergic, Perennial and Seasonal

Australia
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Ukraine, Germany, Peru, Poland, France, Romania, Italy, Mexico
GlaxoSmithKline

Completed

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

Asthma

Australia
GlaxoSmithKline

Completed

QTc Study GSK573719+GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline
Parexel

Completed

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

Asthma

United States
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
Fujifilm Pharmaceuticals U.S.A., Inc.

Recruiting

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

Advanced Solid Tumors

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

Asthma

United States, Argentina, Japan, Poland, Canada, Russian Federation, Spain, Germany, Hungary, South Africa, Italy, Mexico, Romania, Bulgaria, China, Lithuania
Cochlear
Avania

Completed

CP1150 Sound Processor Speech Perception Compared With the Next Generation of Signal Processing Technology

Hearing Impairment, Sensorineural

Australia
GlaxoSmithKline

Completed

A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function

Asthma

New Zealand
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
Fujifilm Pharmaceuticals U.S.A., Inc.

Recruiting

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

Advanced Solid Tumors

United States
Mansoura University

Recruiting

Prosthetic Femoral Access for Haemodialysis

Vascular Access Complication

Egypt
Autoimmune Technologies, LLC
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain

Influenza

United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study

Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer AJCC v8 | Stage III Renal Pelvis and Ureter Cancer AJCC v8 | Stage IV Renal Pelvis and Ureter Cancer AJCC v8 | Stage 0a Renal Pelvis and Ureter Cancer AJCC v8 | Stage... and other conditions

United States
Odense University Hospital

Completed

Antithyroid Drugs During Radioiodine Therapy

Graves Disease | Toxic Nodular Goitre

Denmark

3

Subscribe